Sabin C A, Phillips A N, Lee C A, Janossy G, Emery V, Griffiths P D
Department of Public Health, Royal Free Hospital School of Medicine, London, UK.
Epidemiol Infect. 1995 Apr;114(2):361-72. doi: 10.1017/s095026880005799x.
The effect of prior infection with cytomegalovirus (CMV) on progression of HIV disease in a cohort of 111 men with haemophilia was studied after 13 years follow-up. The relative hazards associated with CMV positivity on progression to AIDS, death and a CD4 count of 0.05 x 10(9)/l were 2.28, 2.42 and 2.34, respectively. CMV seropositive patients were significantly older than the seronegative and this was controlled for by using a Cox proportional hazards model. The relative hazards for the three endpoints decreased to 1.89, 1.82 and 1.93 respectively and were marginally non-significant (P = 0.05, 0.08 and 0.08 for the three endpoints respectively). We conclude that this cohort continues to show evidence of a 'co-factor' effect associated with prior infection with CMV which is confounded by age but not completely explained by age differences. The potential biological significance of these results is discussed in the context of recent controlled clinical trials which show a survival benefit from long-term high-dose acyclovir, a drug with activity in vivo against CMV and other herpesviruses.
在对111名血友病男性患者进行了13年的随访后,研究了既往巨细胞病毒(CMV)感染对HIV疾病进展的影响。CMV阳性与进展为艾滋病、死亡以及CD4细胞计数降至0.05×10⁹/L的相对风险分别为2.28、2.42和2.34。CMV血清阳性患者的年龄显著大于血清阴性患者,通过使用Cox比例风险模型对此进行了控制。三个终点的相对风险分别降至1.89、1.82和1.93,且略无统计学意义(三个终点的P值分别为0.05、0.08和0.08)。我们得出结论,该队列继续显示出与既往CMV感染相关的“协同因子”效应的证据,这种效应受年龄的混淆,但并未完全由年龄差异所解释。在最近的对照临床试验背景下讨论了这些结果的潜在生物学意义,这些试验显示长期高剂量阿昔洛韦具有生存益处,阿昔洛韦是一种在体内对CMV和其他疱疹病毒有活性的药物。